Cited by 142Fatty Acid Research and HealthPeroxisome Proliferator-Activated ReceptorsAdipokines, Inflammation, and Metabolic Diseases

n-3 Fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet

Open access
Kuda, O., Jelenik, T., Jilkova, Z., Flachs, P., Rossmeisl, M., Hensler, M., Kazdova, L., Ogston, N. +10 more·2009·Diabetologia

Abstract

Aims/hypothesis Fatty acids of marine origin, i.e. docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) act as hypolipidaemics, but they do not improve glycaemic control in obese and diabetic patients. Thiazolidinediones like rosiglitazone are specific activators of peroxisome proliferator-activated receptor gamma, which improve whole-body insulin sensitivity. We hypothesised that a combined treatment with a DHA and EPA concentrate (DHA/EPA) and rosiglitazone would correct, by complementary additive mechanisms, impairments of lipid and glucose homeostasis in obesity.Methods Male C57BL/6 mice were fed a corn oil-based high-fat diet. The effects of DHA/EPA (replacing 15% dietary lipids), rosiglitazone (10 mg/kg diet) or a combination of both on body weight, adiposity, metabolic markers and adiponectin in plasma, as well as on liver and muscle gene expression and metabolism were analysed. Euglycaemic-hyperinsulinaemic clamps were used to characterise the changes in insulin sensitivity. The effects of the treatments were also analysed in dietary obese mice with impaired glucose tolerance (IGT).Results DHA/EPA and rosiglitazone exerted additive effects in prevention of obesity, adipocyte hypertrophy, low-grade adipose tissue inflammation, dyslipidaemia and insulin resistance, while inducing adiponectin, suppressing hepatic lipogenesis and decreasing muscle ceramide concentration. The improvement in glucose tolerance reflected a synergistic stimulatory effect of the combined treatment on muscle glycogen synthesis and its sensitivity to insulin. The combination treatment also reversed dietary obesity, dyslipidaemia and IGT.Conclusions/interpretation DHA/EPA and rosiglitazone can be used as complementary therapies to counteract dyslipidaemia and insulin resistance. The combination treatment may reduce dose requirements and hence the incidence of adverse side effects of thiazolidinedione therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-009-1305-z

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kuda, O., Jelenik, T., Jilkova, Z., Flachs, P., Rossmeisl, M., Hensler, M., Kazdova, L., Ogston, N., Baranowski, M., Gorski, J., Janovska, P., Kus, V., Polak, J., Mohamed-Ali, V., Burcelin, R., Cinti, S., Bryhn, M., & Kopecky, J.
Affiliations
  • Czech Academy of Sciences (CZ)
  • University College London (GB)
  • Medical University of Białystok (PL)
  • Charles University (CZ)
  • Inserm (FR)
  • Marche Polytechnic University (IT)
Venue
Diabetologia
Published
2009-03-11
Volume
52
Issue
5
Pages
941-951
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2023838856
Cited by
142
References
50
Citations by year
2026: 2 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 6 · 2020: 9 · 2019: 5 · 2018: 10 · 2017: 6 · 2016: 8 · 2015: 13 · 2014: 10 · 2013: 16 · 2012: 11
FWCI
13.88
Type
journal article
Language
en
Open access
Locations
  • Diabetologia (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • European Commission (LSHMCT-2004-005272)
  • Ministerstvo Školství, Mládeže a Tělovýchovy (1 M6837805002, AV0Z50110509)
  • Grantová Agentura České Republiky (GA303/08/0664, 1M6837805002, AV0Z50110509)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
Keywords
omega-3 fatty acids, docosahexaenoic acid, eicosapentaenoic acid, rosiglitazone, thiazolidinediones, insulin sensitivity, muscle glycogen synthesis, high-fat diet, obesity, insulin resistance, impaired glucose tolerance, dyslipidemia, adiponectin, hepatic lipogenesis, ceramide, adipose tissue inflammation, PPARγ, combination therapy
MeSH terms
Rosiglitazone, Animals, Corn Oil, Dietary Fats, Docosahexaenoic Acids, Glycogen, Hypoglycemic Agents, Insulin, Male, Mice, Inbred C57BL, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Glucose Intolerance, Muscle, Skeletal, Thiazolidinediones, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review